Pharma News & Analysis

Thursday, March 8, 2012

Interview With Pfizer Director on Virtual Clinical Trials

Found an interview of Pfizer Director, regarding virtual clinical trials.

at 10:17:00 PM

Email This BlogThis!Share to Twitter Share to Facebook Share to Pinterest

Newer Post Older Post Home

Subscribe To

Posts

Posts

Comments

Comments

Popular Posts

Funny Clinical Research Cartoons
MenAfriVac, meningitis vaccine administered to 100 millionth person
Novartis drug Ilaris® approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Access to Medicine Index 2012
Chimerix Presents Data Highlighting Burden Of Care Associated With Current Antiviral Therapies In Stem Cell Transplantation
Colleges offering Pharm.D in Andhra Pradesh
FDA agrees to review Merck's Suvorexant for sleeplessness
New drug approved by US FDA for the treatment of COPD
Computer Exercises May Offer New Hope for Alzheimer's Patients
Merck Opens New Manufacturing Facility in Hangzhou, China

Blog Archive

► 2024 (1)
- ► March (1)

► 2023 (16)
- ► November (2)
- ► October (7)
- ► May (7)

► 2022 (13)
- ► September (8)
- ► July (3)
- ► June (1)
- ► April (1)

► 2021 (24)
- ► November (13)
- ► October (8)
- ► September (3)

► 2015 (1)
- ► April (1)

► 2014 (4)
- ► January (4)

► 2013 (44)
- ► December (20)
- ► November (10)
- ► October (2)
- ► September (1)
- ► May (3)
- ► April (8)

▼ 2012 (343)
- ► December (2)
- ► November (5)
- ► September (112)
- ► August (197)
- ► July (5)
- ► April (4)
- ▼ March (10)
- ► February (3)
- ► January (5)

► 2011 (121)
- ► December (19)
- ► October (9)
- ► September (11)
- ► August (30)
- ► June (9)
- ► May (8)
- ► April (14)
- ► March (11)
- ► February (6)
- ► January (4)

► 2010 (105)
- ► December (31)
- ► November (10)
- ► August (1)
- ► June (7)
- ► April (9)
- ► March (4)
- ► February (24)
- ► January (19)

► 2009 (222)
- ► December (23)
- ► November (6)
- ► October (9)
- ► September (16)
- ► August (62)
- ► July (32)
- ► June (31)
- ► May (17)
- ► March (15)
- ► February (11)

► 2008 (29)
- ► December (4)
- ► September (1)
- ► July (2)
- ► June (6)
- ► May (1)
- ► April (5)
- ► March (7)
- ► January (3)

► 2007 (3)
- ► December (2)
- ► October (1)

Topics

pharma (171) regulation (82) drugs (81) Regulatory (63) News (57) Education (55) clinical (51) clinical research (49) FDA (45) clinical trials (40) conference (29) swine flu (28) DCGI (27) Approval (25) India (25) workshop (25) markets (23) admission (19) colleges (19) company news (19) patent (19) seminar (19) job (18) research (18) vacancy (15) courses (14) IPR (11) pharm.d (11) pharmacy (11) New drugs (10) vaccines (10) IPC (9) M.Pharm (9) statistics (9) training (9) CRO (8) WHO (8) cancer (8) diseases (8) government (8) Pharmacopoeia (7) oncology (7) Awards (6) NIPER (6) Pfizer (6) expo (6) healthcare (6) people (6) sales (6) BMS (5) FDC (5) GSK (5) Industry (5) NPPA (5) PCI (5) diabetes (5) exports (5) guidance (5) spurious drugs (5) DTAB (4) DoP (4) ban (4) biotech (4) career (4) certification (4) diagnostics (4) journals (4) pharmacovigilance (4) teaching (4) CDSCO (3) Devices (3) FICCI (3) GATE (3) ICMR (3) IDMA (3) Malaria (3) Novartis (3) Roche (3) articles (3) banned drugs (3) blog (3) generics (3) interview (3) job cuts (3) law (3) market research (3) policy (3) recruitment (3) technology (3) virtual clinical trials (3) AICTE (2) AIDS (2) AIIMS (2) AstraZeneca (2) Ayush (2) BCG (2) Biocon (2) CDA (2) China (2) DLBCL (2) Deal (2) Discovery (2) EMEA (2) Europe (2) GMP (2) HIV (2) Hospital (2) IMS (2) IND (2) IPA (2) Maharastra (2) Manufacturing (2) Merck (2) Ranbaxy (2) SRF (2) Sanofi (2) Strategy (2) Weight loss (2) abstacts (2) adverticle (2) biosimilars (2) chikungunya (2) counselling (2) fraud (2) funny (2) machinery (2) manipal (2) marketing (2) meeting (2) merger (2) pharmacology (2) pricing (2) project (2) side effects (2) tamilnadu (2) testing (2) treatment (2) videos (2) ACTE (1) AIPS (1) ASBMR (1) Access to Medicine (1) Africa (1) Amylin (1) Ardea (1) Arthritis (1) Atropa (1) Awareness (1) BA/BE (1) BITS Pilani (1) British (1) CBER (1) CCMB (1) CCRH (1) CEP (1) CFDA (1) CHMP (1) CII (1) COPD (1) CPHl (1) Chronic Diseases (1) ClinicalTrials.gov (1) Colchicine (1) Crowdsourcing (1) DBT (1) DCA (1) DPCO (1) DPST (1) DST (1) Dapagliflozin (1) Diabetic retinopathy (1) Diptheria (1) Drug discontinuation (1) Drug inspector (1) Elder (1) Electroceuticals (1) Events (1) FDCA (1) FGSCDA (1) FMRAI (1) Febuxostat (1) Formulary (1) GDP (1) GOBIOM (1) GPAT (1) GVK (1) Gene (1) Gout (1) H1N1 (1) HPV (1) Heart failure (1) Hepatitis (1) ICT (1) ILDS (1) IPGA (1) IPSCON (1) IRB (1) ISCR (1) Import (1) Infants (1) Influenza (1) Innocentive (1) Insomnia (1) Internet (1) Investment (1) JOVE (1) JRF (1) JnJ (1) KDPMA (1) Launch (1) Lilly (1) MBA (1) MCI (1) MHRA (1) MedImmune (1) Media (1) Medical (1) Medical Tourism (1) Medicine (1) Medicines (1) Meningitis (1) Monographs (1) Mutation (1) NDA (1) Nanomedicine (1) Neuroscience (1) OAB (1) Obesity (1) Operations (1) Osteoarthritis (1) Ozone Pharma (1) Pharma Industry (1) Pharmexcil (1) Phase IV (1) Pipeline (1) Pneumonia (1) Preclinical (1) QA (1) QIP (1) Reference (1) SMS (1) Smoking (1) Standards (1) Sun Pharma (1) TB (1) TNCDA (1) Takeda (1) Teijin (1) Tetanus (1) Thyroid (1) Tobacco (1) UGC (1) UK (1) URL pharma (1) US (1) Wyeth (1) accredition (1) adverse effects (1) albinism (1) alternative medicine (1) amgen (1) bihar (1) bill (1) biomarker (1) biopharm (1) brain fever (1) budget (1) campaign (1) cisapride (1) contest (1) counterfeit (1) court (1) cpcsea (1) cytrx (1) degree (1) delhi (1) depression (1) device (1) diet (1) draft (1) drugs control (1) economy (1) ethics (1) exam (1) faculty (1) grants (1) hyderabad (1) info (1) informed consent (1) innovation (1) inspection (1) international (1) jobs (1) karnataka (1) kerala (1) lab (1) lesinurad (1) loans (1) misconduct (1) new year (1) nimesulide (1) novo nordisk (1) nuts (1) orchid (1) osteoporosis (1) overpricing (1) parliament (1) peanuts (1) pharmacogenomics (1) phase I (1) pictures (1) pollution (1) product safety (1) profit (1) rajasthan (1) recognition (1) report (1) resistance (1) reward (1) salary (1) scholarships (1) serum institute (1) sibutramine (1) skin cancer (1) soft tissue sarcoma (1) sri lanka (1) stiefel (1) stockists (1) support (1) survey (1) symposia (1) tanzania (1) thanks (1) transplantation (1) updates (1) virus (1) what to name it (1) youtube (1)

Copyright© 2016, Pharma News & Analysis. Powered by Blogger.